Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Chugai Files Tecentriq in Adjuvant Use for MRD-Positive Bladder Cancer
Chugai Pharmaceutical said on January 28 that it has filed its PD-L1 inhibitor Tecentriq (atezolizumab) in Japan for an additional indication as an adjuvant therapy for patients with minimal residual disease (MRD)-positive bladder cancer.If approved, the expanded label would provide…
To read the full story
BUSINESS
- Takeda Rejigs Structure Ahead of CEO Transition, Creates New International Unit
January 30, 2026
- Chugai Logs Solid 2025 Results on Overseas Growth, Profit Margin Nears 50%
January 30, 2026
- Zynlonta Hits Primary Endpoint in Japanese PI/II Study: Tanabe
January 30, 2026
- Towa Chief Urges Better Use of Innovators’ LLP Manufacturing Assets, Calls Otsuka Deal a “First Step”
January 30, 2026
- Takeda Raises Full-Year Forecast on Weaker Yen Assumptions
January 30, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…